logo
Share SHARE
FONT-SIZE Plus   Neg

NovaBay Pharma, Virbac Animal Health Ink Option Deal For Aganocide Compounds

NovaBay Pharmaceuticals Inc. (NBY) said it has reached a feasibility and option agreement with Virbac Animal Health for the development and potential commercialization of Aganocides for a number of veterinary use. As per the deal, NovaBay would receive an upfront payment plus additional support for research and development.

Virbac would conduct veterinary studies using NovaBay's Aganocide compounds in order to assess feasibility for treating several veterinary indications, and it would have the option to license exclusive worldwide rights to market Aganocides for one or more of these indications. If exercised, NovaBay may receive additional payments, including an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. Also, NovaBay would receive royalties on sales of any commercialized Aganocide products to arise from this agreement.

NovaBay is developing its first-in-class, non-antibiotic, anti-infective Aganocide compounds for the topical treatment and prevention of a wide variety of bacterial, viral and fungal infections.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
HSBC is reportedly laying off about 100 of its senior investment bankers worldwide, as the banking giant strives to curb operating costs. According to reports, the London-headquartered bank will eliminate managing director and director level employees at the Global Banking and Markets division, as... Samsung Electronics Co., Ltd. (SMSN.L, SSNNF.OB, SSNLF.OB) will reportedly blame faulty batteries for last year's Galaxy Note 7 fiasco. According to a Wall Street Journal report, Samsung's investigation of Galaxy Note 7 smartphones found that some batteries were irregularly sized while others had... Federal investigators have closed their probe of a fatal crash that involved a Tesla Motors Inc. car eight months ago. The regulators said they have found no safety defects in the vehicle's automated driving system and that Tesla's Autopilot-enabled vehicles did not need to be recalled.
comments powered by Disqus
Follow RTT